About RxWare
RxWare is a private company based in Wilmington, Delaware. It has reported $10,689,268 raised in four offerings on Form D since October 2019. Its chief executive is Raeanna Lewarne.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | Aug 14, 2025 | $6,144,268of $6.7M target | 12 | $512K | Equity, OptionsRule 506(b) | Form D ↗ |
| Nov 15, 2024 | Dec 2, 2024 | $225,000of $1.1M target | 3 | $75,000 | OptionsRule 506(b) | Form D ↗ |
| Apr 22, 2024 | May 7, 2024 | $700,000of $1.0M target | 4 | $175K | OptionsRule 506(b) | Form D ↗ |
| Sep 19, 2019 | Oct 4, 2019 | $3,620,000of $6.0M target | 4 | $905K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $10,689,268 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RxWare's Form D filed Aug 14, 2025.
DM
David Matias
Director
RL
Raeanna Lewarne
Chief Executive Officer and director
SA
Shlomi Aflalo
Executive officer and director
HT
Harry Totonis
Director
FA
Farhan Ashraf
Director
AF
Adam Fine
Director
Earlier filings also listed Gregg Dearhammer (director, last listed Dec 2024), Aaron Ganz (executive officer, last listed May 2024), Yishai Knobel (chief executive officer and director, last listed Oct 2019) and Ori Karev (director, last listed Oct 2019).